The National PHL Drug Susceptibility Testing (DST) Reference Center for
Mycobacterium tuberculosis (MTBC) provides quality-assured drug susceptibility testing for eligible US public health laboratories with low volumes of testing. The Reference Center serves as an extension of CDC’s Division of TB Elimination Laboratory Branch providing services that are harmonized with and complementary to those available at CDC. California Department of Public Health’s Microbial Diseases Laboratory serves as the Reference Center.
Enrollment is restricted to public health laboratories performing TB DST on fewer than 50 isolates per year. Participation in the reference center is voluntary.
CDC’s testing services remain available to all US TB Programs. Jurisdictions that are not eligible to enroll may still submit specimens and/or isolates to CDC for the Molecular Detection of Drug Resistance (MDDR) or second-line DST.
The National PHL DST Reference Center for MTBC will provide the following services at no cost to eligible submitting PHLs:
First-Line DST using MGIT with a panel of rifampin, isoniazid, pyrazinamide and ethambutol
DST for 4-month rifapentine-moxifloxacin regimen using MGIT with a panel of rifampin, isoniazid, pyrazinamide and moxifloxacin
Second-Line DST using MGIT with a panel of ethionamide, capreomycin, amikacin, moxifloxacin, kanamycin and rifabutin
Molecular detection of drug resistance will be performed by whole genome sequencing on submitted isolates and by pyrosequencing on specimen sediments, mixed and non-viable cultures
Whole genome sequencing data will be shared with the CDC for the purpose of national molecular surveillance
Resources for Submitting Laboratories
Please direct questions to Sarah Buss (email@example.com)